Disseminated fungal infection in a patient receiving zanubrutinib

We report a case of fatal disseminated aspergillosis in the setting of administration of zanubrutinib, a second‐generation Bruton's tyrosine kinase inhibitor thought to have a lower rate of immunosuppression‐related side effects.

Detalles Bibliográficos
Autores principales: Walsh, Madalyn, Xu, Alice, Ballas, Zuhair, Sanchez, Rolando
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10264913/
https://www.ncbi.nlm.nih.gov/pubmed/37323284
http://dx.doi.org/10.1002/ccr3.7564
Descripción
Sumario:We report a case of fatal disseminated aspergillosis in the setting of administration of zanubrutinib, a second‐generation Bruton's tyrosine kinase inhibitor thought to have a lower rate of immunosuppression‐related side effects.

Ejemplares similares